Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine

Cancer Research

Volumn 63, Issue 7, 2003, Pages 1520-1526

  Yang, Bo ^c   Keshelava, Nino ^c   Anderson, Clarke P ^a   Reynolds, C Patrick ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c Children's Hospital Los Angeles ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; REDUCING AGENT; TIRAPAZAMINE;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; HYPOXIA; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BUTHIONINE SULFOXIMINE; CELL HYPOXIA; DRUG SYNERGISM; GLUTATHIONE; HUMANS; INTRACELLULAR MEMBRANES; MEMBRANE POTENTIALS; MITOCHONDRIA; NEUROBLASTOMA; OXYGEN; REACTIVE OXYGEN SPECIES; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0037382334     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Reynolds, C. P., and Seeger, R. C. Neuroblastoma. In: C. M. Haskell (ed.), Cancer Treatment, Ed. 5, pp. 1214-1236. Philadelphia: W. B. Saunders, 2000.
2. Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., Gerbing, R. B., and Reynolds, C. P. Treatment of high-risk neoroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med., 341: 1165-1173, 1999.
3. Grant, J. L., and Smith, B. Bone marrow gas tensions, bone marrow blood flow, and erythropoiesis in man. Ann. Intern. Med., 58: 801-809, 1963.
4. Matthay, K. K., Atkinson, J. B., Stram, D. O., Selch, M., Reynolds, C. P., and Seeger, R. C. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children's Cancer Group pilot study. J. Clin. Oncol., 11: 2226-2233, 1993.
5. Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, N. S., Luna, M. C., Gomer, C. J., Triche, T. J., and Reynolds, C. P. Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. Cancer Res., 61: 5103-5105, 2001.
6. Dachs, G. U., and Tozer, G. M. Hypoxia modulated gene expression: angiogenesis, metastasis, and therapeutic exploitation. Eur. J. Cancer, 36: 1649-1660, 2000.
7. Tew, K. D., Houghton, P. J., and Houghton, J. A. Preclinical and clinical modulation of anticancer drugs, Preclinical, and clinical modulation of anticancer drugs, pp. 13-17. Boca Raton: CRC Press, 1993.
8. Meister, A., and Anderson, M. E. Glutathione. Annu. Rev. Biochem., 52: 711-760, 1983.
9. Anderson, C. P., Tsai, J. M., Meek, W. E., Liu, R. M., Tang, Y., Forman, H. J., and Reynolds, C. P. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp. Cell Res., 246: 183-192, 1999.
10. Schroder, C. P., Godwin, A. K., O'Dwyer, P. J., Tew, K. D., Hamilton, T. C., and Ozols, R. F. Glutathione and drug resistance. Cancer Investig., 14: 158-168, 1996.
11. Meijer, C., Mulder, N. H., Timmer Bosscha, H., Sluiter, W. J., Meersma, G. J., and de Vries, E. G. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res., 52: 6885-6889, 1992.
12. Somfai Relic, S., Suzukake, K., Vistica, B. P., and Vistica, D. T. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem. Pharmacol., 33: 485-490, 1984.
13. Siemann, D. W., and Beyers, K. L. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Br. J. Cancer, 68: 1071-1079, 1993.
14. Anderson, C. P., and Reynolds, C. P. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell liens established at relapse after myeloablative therapy. Bone Marrow Transplant., 30: 135-140, 2002.
15. Anderson, C. P., Keshelava, N., Satake, N., Meek, W. H., and Reynolds, C. P. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Med. Pediatr. Oncol., 35: 659-662, 2000.
16. Anderson, C. P., Seeger, R. C., Statake, N., Monforte-Munoz, H. L., Keshelava, N., Bailey, H. H., and Reynolds, C. P. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J. Pediatr. Hematol. Oncol, 23: 500-505, 2001.
17. Workman, P., and Stratford, I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev., 12: 73-82, 1993.
18. Saunders, M. P., Patterson, A. V., Chinje, E. C., Harris, A. L., and Stratford, I. J. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br. J. Cancer, 82: 651-656, 2000.
19. Evans, J. W., Yudoh, K., Delahoussaye, Y. M., and Brown, J. M. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res., 58: 2098-2101, 1998.
20. Craighead, P. S., Pearcey, R., and Stuart, G. A Phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys., 48: 791-795, 2000.
21. Patterson, A. V., Saunders, M. P., Chinje, E. C., Patterson, L. H., and Stratford, 1. J. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des., 13: 541-573, 1998.
22. Dorie, M. J., Kovacs, M. S., Gabalski, E. C., Adam, M., Le, Q. T., Bloch, D. A., Pinto, H. A., Terris, D. J., and Brown, J. M. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia, 1: 461-467, 1999.
23. Clement, J. J., Gorman, M. S., Wodinsky, I., Catane, R., and Johnson, R. K. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res., 40: 4165-4172, 1980.
24. Goldberg, Z., Evans, J., Birrell, G., and Brown, J. M. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin. Int. J. Radiat. Oncol. Biol. Phys., 49: 175-182, 2001.
25. Masunaga, S., Ono, K., Hori, H., Suzuki, M., Kinashi, Y., Takagaki, M., Kasai, S., Nagasawa, H., and Uto, Y. Change in oxygenation status in intratumour total and quiescent cells following γ-ray irradiation, tirapazamine administration, cisplatin injection and bleomycin treatment. Br. J. Radiol, 73: 978-986, 2000.
26. Jounaidi, Y., and Waxman, D. J. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res., 60: 3761-3769, 2000.
27. Wouters, B. G., Wang, L. H., and Brown, J. M. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann. Oncol. 10 (Suppl. 5): S29-S33, 1999.
28. Kovacs, M. S., Hocking, D. J., Evans, J. W., Siim, B. G., Wouters, B. G., and Brown, J. M. Cisplatin anti-turnout potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer, 80: 1245-1251, 1999.
29. Reynolds, C. P., Biedler, J. L., Spengler, B. A., Reynolds, D. A., Ross, R. A., Frenkel, E. P., and Smith, R. G. Characterization of human neuroblastoma cell lines established before and after therapy. J. Natl. Cancer Inst. (Bethesda), 76: 375-387, 1986.
30. Maurer, B. J., Melton, L., Billups, C., Cabot, M. C., and Reynolds, C. P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. (Bethesda), 92: 1897-1909, 2000.
31. Maurer, B. J., Metelitsa, L. S., Seeger, R. C., Cabot, M. C., and Reynolds, C. P. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J. Natl. Cancer Inst. (Bethesda), 91: 1138-1146, 1999.
32. Vaupel, P., Schlenger, K., Knoop, C., and Hockel, M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res., 51: 3316-3322, 1991.
33. Proffitt, R. T., Tran, J. V., and Reynolds, C. P. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry, 24: 204-213, 1996.
34. Keshelava, N., Seeger, R. C., Groshen, S., and Reynolds, C. P. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res., 58: 5396-5405, 1998.
35. Chou, J., and Chou, T. C. Dose effect analysis with microcomputers. Dose effect analysis with microcomputers. Cambridge, United Kingdom: Elsevier-Biosoft, 1988.
36. Chou, T. C. Drug combinations: from laboratory to practice. J. Lab Clin. Med., 132: 6-8, 1998.
37. Vandeputte, C., Guizon, I., Genestic-Denis, I., Vannier, B., and Lorenzon, G. A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: performance study of a new miniaturized protocol. Cell Biol. Toxicol., 10: 415-421, 1994.
38. Royall, J. A., and Ischiropoulos, H. Evaluation of 2′,7′-dichlorofluorescin and dihydrorhodamine 123 as fluorescent probes for intracellular H2O2 in cultured endothelial cells. Arch. Biochem. Biophys., 302: 348-355, 1993.
39. Sakahira, H., Enari, M., and Nagata, S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature (Lond.), 391: 96-99, 1998.
40. Poulaki, V., Mitsiades, N., Romero, M. E., and Tsokos, M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res., 61: 4864-4872, 2001.
41. Susin, S. A., Zamzami, N., and Kroemer, G. Mitochondria as regulators of apoptosis: doubt no more. Biochim. Biophys. Acta, 1366: 151-165, 1998.
42. Mancini, M., Anderson, B. O., Caldwell, E., Sedghinasab, M., Paty, P. B., and Hockenbery, D. M. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J. Cell Biol., 138: 449-469, 1997.
43. Bailey, H. H., Ripple, G., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Mahvi, D., Schink, J., Pomplun, M., Mulcahy, R. T., and Wilding, G. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J. Natl. Cancer Inst. (Bethesda), 89: 1789-1796, 1997.
44. Shulman, L. N., Buswell, L., Riese, N., Doherty, N., Loeffler, J. S., von Roemeling, R. W., and Coleman, C. N. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int. J. Radiat. Oncol. Biol. Phys., 44: 349-353, 1999.
45. Brown, J. M., and Koong, A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study [see comments]. J. Natl. Cancer Inst. (Bethesda), 83: 178-185, 1991.
46. Anderson, C. P., Seeger, R. C., Bailey, H. H., and Reynolds C.P. Pilot study of buthionine sulfoximine (BSO) combined with non-myeloablative melphalan (L-PAM) against refractory neuroblastoma (NB). Proc. Amer. Soc. Clin. Oncol., 21: 298a, 2002.
47. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67: 1163-1170, 1993.
48. Moral, A., Lafuente, M. J., Lafuente, A., Castel, T., Balesta, A. M., and Trias, M. L. The use erythrocyte glutathione as a predictive marker for malignant melanoma. Anticancer Res., 20: 4757-4760, 2000.
49. Kearns, P., Pieters, R., Rottier, M. M., Veerman, A. J., Schmiegalow, K., Pearson, A. D., and Hall, A. G. Glutathione in childhood acute leukaemias. Adv. Exp. Med. Biol., 457: 211-216, 1999.
50. Yao, K. S., Godwin, A. K., Johnson, S. W., Ozols, R. F., O'Dwyer, P. J., and Hamilton, T. C. Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res., 55: 4367-4374, 1995.
51. Mulcahy, R. T., Untawale, S., and Gipp, J. J. Transcriptional up-regulation of γ-glutamylcysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells. Mol. Pharmacol., 46: 909-914, 1994.
52. Hall, A. G. Review: The role of glutathione in the regulation of apoptosis. Eur. J. Clin. Investig., 29: 238-245, 1999.
53. Yang, C. F., Shen, H. M., and Ong, C. N. Intracellular thiol depletion causes mitochondrial permeability transition in ebselen-induced apoptosis. Arch. Biochem. Biophys., 380: 319-330, 2000.
54. Kondo, M., Oya-Ito, T., Kumagai, T., Osawa, T., and Uchida, K. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J. Biol. Chem., 276: 12076-12083, 2001.
55. Serafino, A., Sinibaldi-Vallebona, P., Lazzarino, G., Tavazzi, B., Di Pierro, D., Rasi, G., and Ravagnan, G. Modifications of mitochondria in human tumor cells during anthracycline-induced apoptosis. Anticancer Res., 20: 3383-3394, 2000.
56. Kroemer, G., Zamzami, N., and Susin, S. A. Mitochondrial control of apoptosis. lmmunol. Today, 18: 44-51, 1997.
57. Wilson, M. R. Apoptotic signal transduction: emerging pathways. Biochem. Cell Biol., 76: 573-582, 1998.
58. Zou, H., Li, Y., Liu, X., and Wang, X. An APAF-1, cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem., 274: 11549-11556, 1999.
59. Susin, S. A., Lorenzo, H. K., Zamzami, N., Matzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., Goodlett, D. R., Aebersold, R., Siderovski, D. P., Penninger, J. M., and Kroemer, G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (Lond.), 397: 441-446, 1999.
60. Scaffidi, C., Schmitz, I., Zha, J., Korsmeyer, S. J., Krammer, P. H., and Peter, M. E. Differential modulation of apoptosis-sensitivity in CD95 type I and type II cells. J. Biol. Chem., 274: 22532-22538, 1999.
61. Reed, J. C. Bcl-2 family proteins. Oncogene, 17: 3225-3236, 1998.